Exelixis Posts Preliminary '25 Results, Issues '26 Outlook

EXEL posts approximately $2.32B in 2025 revenues and guides $2.525 -$2.625B for 2026 as Cabometyx grows and a zanzalintinib NDA advances.

Zacks Investment Research • 8 hours ago

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, works toward building a potential second commercial franchise with zanzalintinib and moves its earlier.

Business Wire • Jan 11, 2026

Here's Why Exelixis (EXEL) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jan 9, 2026

EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study

Exelixis teamed with Natera on the phase III STELLAR-316 study testing zanzalintinib in resected stage II/III colorectal cancer. Stock gains.

Zacks Investment Research • Jan 8, 2026

2 Healthcare Stocks to Buy for 2026 and Beyond

Axsome Therapeutics and Exelixis are generating solid revenue with their current lineups. Both have promising late-stage candidates that should allow them to expand their portfolios.

The Motley Fool • Jan 8, 2026

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

ALAMEDA, Calif. & AUSTIN, Texas--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 pivotal trial will evaluate zanzalintinib, Exelixis' novel oral kinase inhibitor, with and without an immune checkpoint inhibitor, in patients with resected stage II/III colorectal cancer (CRC). Using Natera's Signatera™ t.

Business Wire • Jan 7, 2026

Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 5:15 p.m. PT / 8:15 p.m. ET. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location for at.

Business Wire • Jan 6, 2026

See How Rare Bullish Inflows Lift Outliers Like Exelixis

Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, is up 81% since a Big Money boost starting in 2021.

FXEmpire • Dec 31, 2025

Here's Why Exelixis (EXEL) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Dec 31, 2025

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Dec 30, 2025